ALNY

Alnylam Pharmaceuticals, Inc. Press Releases

$78.1
*  
0.50
0.64%
Get ALNY Alerts
*Delayed - data as of Sep. 30, 2014  -  Find a broker to begin trading ALNY now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Alnylam to Webcast Presentation at Leerink Partners Rare Disease Roundtable
9/24/2014 4:00:00 PM - Business Wire

Alnylam Initiates DISCOVERY, a Screening Study Examining the Prevalence of Transthyretin (TTR) Mutations in Patients Suspected of Having Cardiac Amyloidosis
9/24/2014 8:00:00 AM - Business Wire

Alnylam to Webcast Presentation at 21st Annual NewsMakers in the Biotech Industry Conference
9/19/2014 4:00:00 PM - Business Wire

Alnylam Presents New Pre-Clinical Data with ALN-CC5, a Subcutaneously Administered RNAi Therapeutic Targeting Complement Component C5 in Development for the Treatment of Complement-Mediated Diseases
9/16/2014 8:00:00 AM - Business Wire

Alnylam Strengthens Management Team with New Key Appointments
9/15/2014 8:00:00 AM - Business Wire

Alnylam Broadens Pipeline with ALN-AGT, a Subcutaneously Administered RNAi Therapeutic Targeting Angiotensinogen (AGT) for the Treatment of Hypertensive Disorders of Pregnancy (HDP), Including Preeclampsia
9/12/2014 8:00:00 AM - Business Wire

Alnylam to Webcast Presentation at Morgan Stanley Global Healthcare Conference
9/3/2014 4:00:00 PM - Business Wire

Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering RNAi-Mediating, Double-Stranded Molecules of 19 to 52 Nucleotides in Length
8/27/2014 8:00:00 AM - Business Wire

Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering RNAi-Mediating Double-Stranded Molecules Comprising Up to 25 Base Pairs
8/20/2014 8:00:00 AM - Business Wire

Alnylam Pharmaceuticals Reports Second Quarter 2014 Financial Results and Highlights Recent Period Activities
8/7/2014 4:00:00 PM - Business Wire

The Medicines Company and Alnylam Pharmaceuticals to Host RNAi Roundtable Webcast “ALN-PCSsc for the Treatment of Hypercholesterolemia”
8/7/2014 9:42:00 AM - Business Wire

Alnylam Receives Orphan Drug Designations in the European Union for ALN-AT3, an RNAi Therapeutic in Development for the Treatment of Hemophilia
8/7/2014 8:00:00 AM - Business Wire

Alnylam to Webcast Conference Call Discussing Second Quarter 2014 Financial Results
7/31/2014 4:00:00 PM - Business Wire

Alnylam to Host Additional Events in “RNAi Roundtable” Webcast Series
7/29/2014 8:00:00 AM - Business Wire

BIOPHARMA INDUSTRY LEADER AMY SCHULMAN JOINS POLARIS PARTNERS
7/29/2014 7:05:00 AM - GlobeNewswire

Alnylam Receives Notice of Allowance from United States Patent and Trademark Office (USPTO) for New Patent Broadly Covering Conjugate-Based Delivery of RNA Therapeutics
7/22/2014 8:00:00 AM - Business Wire

Alnylam to Host “RNAi Roundtable” Webcast Series
7/7/2014 8:00:00 AM - Business Wire